For investors and venture capitalists in the pharmaceutical and biotech sectors, value is created not just through innovation but through strategic decisions that reduce risk and improve efficiency. The integration of human tissue testing into the drug development processis an example of such decisions. Testing drug candidates on fresh or frozen human tissue reduces reliance on animal models, which often fail topredict human responses accurately.Only ~1 in 5,000-10,000 compounds in development [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.